However, despite treatment with current antifibrotic medications, most patients with pulmonary fibrosis still suffer from ...

Sleep apnea, or specifically obstructive sleep apnea (OSA), is linked to hypertension (high blood pressure). OSA affects 30% ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

Columnist Anna Jeter was recently reminded that she's still absorbing lessons from her chronic illness after 25 years of ...

Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report highlighted climate change, cardiovascular risk ...

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, ...

Positive results from a study of Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming ...

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim ...

Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...

Winrevair was approved to treat pulmonary arterial hypertension (PAH), a progressive disorder caused by a constriction of ...

Merck , known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary ...